Constipation is often treated as a simple plumbing problem, too little movement, too much delay. But emerging research ...

A newly approved option for pediatric patients with functional constipation significantly increased the frequency of bowel movements and improved other burdensome symptoms as well, according to a ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The overall response rates to washed microbiota ...

The health service constitutes constipation as being bowel movements that are fewer than three each week, which can lead to symptoms like painful cramps in the tummy area, straining to poo, or not ...

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a leading global gastrointestinal healthcare company, will present findings during the 2023 North American Society for Pediatric ...

Prenatal exposure to selective serotonin reuptake inhibitors (SSRIs) is associated with an increased risk of functional constipation developing in offspring, according to a study published online Dec.

Credit: Shutterstock. Linzess is a guanylate cyclase-C agonist. The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the treatment of functional constipation (FC) in ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Linzess, the first therapy for pediatric functional constipation in patients aged 6 to 17 ...

How often do you poop? Yes, this is a very TMI question, but an important one. Constipation, where you’re pooping less than three times a week, is one of the most common gastrointestinal complaints ...

(RTTNews) - Ironwood Pharmaceuticals, Inc. (IRWD), Monday announced that the U.S. Food and Drug Administration has approved Linzess (linaclotide) as a once-daily treatment for pediatric patients ages ...

There are no known causes and usually multiple factors leading to the common condition that makes stools hard and difficult to pass, according to the FDA. Linzess was approved in 2012 for adult ...

The US Food and Drug Administration (FDA) has expanded the indication for linaclotide (Linzess) to children as young as age 6 years with functional constipation, making it the first approved treatment ...